In comparison, use of the serum markers CA15-3 and CEA, commonly used to detect recurrence and metastasis in breast cancer patients in clinical practice, exhibited lower sensitivity (54.3 and 32.6%, respectively) and AUC values (0.737 and 0.639, respectively) (Fig. 2G). This evidence concerns the gene CEACAM5 and breast carcinoma.